Pseudomonas aeruginosa is a common opportunistic pathogen which can cause fatal infections in vulnerable hosts. It is the primary pulmonary pathogen in patients with cystic fibrosis (CF) and elicits significant morbidity in patients with thermal burns, cancer, and an immunosuppressed status (15) . The pathogenesis of P. aeruginosa is multifactorial and involves a large number of extracellular products which may act as bacterial virulence factors (5, 11, 18) . Among them, elastase, a Zn-metalloproteinase produced by most clinical strains of P. aeruginosa, has been largely characterized (12, 13) . The elastase gene has been cloned and sequenced, and its mature protein product has been identified as a 32,926-to 33,000-Da polypeptide with a fully defined amino acid sequence (1, 2) . Despite recent documentation of its complete primary structure (2, 7) , little is known about the immunochemistry of elastase, and no specific epitopes have been identified or characterized in this protein molecule. To the best of our knowledge, no monoclonal antibodies (MAbs) that react with P. aeruginosa elastase have yet been identified.
In the present study, we isolated and characterized six MAbs which react specifically with P. aeruginosa elastase. Using a competition assay, these MAbs were shown to react to four different epitopes on elastase. Antigenic conservation studied with the MAbs was demonstrated for two of these epitopes among all clinically testqd and representative strains of the International Antigen Typing Scheme (IATS) positive for P. aeruginosa elastase activity. P. aeruginosa PA103 was chosen for its absence of detectable elastase and P. aeruginosa 388 leu::Tnl was chosen because of its known capacity to secrete elastase (16 BALB/c mice were immunized once a week for 4 weeks. For the first immunization, thXy were inoculated intraperitoneally with 10 ,ug of purified elastase (Nagase Biochemicals, Osaka, Japan) emulsified in an equal amount of complete Freund adjuvant (GIBCO Laboratories, Grand Island, N.Y.). For immunizations 2 through 4, the mice were given the immunogen intraperitoneally in incomplete Freund adjuvant. Serum titers of antibodies to elastase were determined by enzyme-linked immunosorbent assay (ELISA) (as outlined below) and were 1: 10,000 in the mice selected for use in the MAb isolation.
For MAb production, the method described by l3rodeur et al. (3) was used with modifications. The spleens from selected mice were removed 3 days after the last injection for fusion with the mouse myeloma cell line P3-X63-Ag8-U1 (American Type Culture Collection) at a 10:1 ratib, employing 50% polyethylene glycol 1500 (Kodak) as a fusogen. RPMI 1649 medium (GIBCO) used for growth of the fused cells was supplemented with 20% fetal calf serum (GIBCO), 2 mM glutamine, 100 FM hypoxanthine, 1 ,M aminopterin, 16 ,uM thymidine, 50 ,ug of gentamicin per ml, and 104 normal m,use peritoneal cells per 0.2 ml. MAb titration was performed by ELISA. The hybridoma was subcloned three times by limiting dilution in 96-well plates (Nunc, GIBCO) in the same medium without aminopterin. MAbs were pro-duced in large quantities in 75-cm2 tissue culture flasks and in mouse ascitic fluid. MAbs in ascitic fluid were partially purified by precipitation with 50% ammonium sulfate. Hybridoma culture supernatants were obtained from cells transferred at a high concentration (4 x 106 per ml) in culture medium without fetal calf serum for 3 days and partially purified by precipitation with polyethylene glycol 6000 (Fisher, Montreal, Quebec, Canada) for 2 h at 4°C at a final concentration of 10% (wt/vol) (6) . Purified MAbs were conjugated to biotin as described elsewhere (19) . Briefly, purified MAbs (10 mg/ml) in 100 mM carbonate buffer (pH 8.5) were mixed with 0.1 volume of a fresh N,N-dimethylformamide solution (Fisher) in 6 mg of biotinyl-N-hydroxysuccinimide (Sigma) per ml. The mixture was allowed to react for 1 h at room temperature, dialyzed against PBS until free of biotin, and frozen at -70°C in aliquots. ELISA was performed as described previously (10), using a commercial preparation of purified elastase (Nagase Biochemicals) as a coating antigen at a final concentration of 2 ,ug/ml in 0.05 M sodium carbonate buffer (pH 9.6). The 96-well plates (Nunc, GIBCO) were incubated overnight at room temperature. Controls included unrelated MAb and preimmune and immune mouse sera. Preliminary studies have shown that the elastase enzyme used as a coating antigen did not manifest immunoglobulin G (IgG) proteolytic activity in our ELISA protocol.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SI)S-PAGE) was performed under reducing conditions by the Laemmli method (9) in a minigel system (Bio-Rad Laboratories, Richmond, Calif.). Electrophoresis was conducted in 12% slab gels at 200 V for 50 min, using appropriate molecular weight markers (Bio-Rad Laboratories). Subs'equently, the gels were either stained with silver nitrate (Canlab, Toronto, Ontario, Canada) as described previously (14) or electrophoretically transferred to nitrocellulose by the method of Towbin et al. (20) . Electrophoretic transfers onto nitrocellulose (Bio-Rad Laboratories) were performed at 100 V for 60 min. Immunospecific reactions were detected by autoradiography (8) or with avidin-peroxidase conjugates used in concert with biotinylated secondary antibodies according to the manufacturer's recommendations (Vector Laboratories, Burlingame, Calif.). To assess whether MAbs recognize the same epitopes, we performed a competitive binding assay using ELISA essentially as described above unless otherwise specified. Wells of polystyrene microdilution plates were coated with 100 RI of purified elastase at a concentration of 0.5 ,ug/ml as determined by preliminary assays with biotinylated MAb dilutions to optimize assay conditions. After the blocking step, 50 ,ul of MAb undiluted culture supernatant was added in triplicate to each well. The MAbs were allowed to bind to elastase for 30 min at room temperature. Then, 50 pul of a biotinylated MAb dilution per well was added. Plates were incubated for 1 h at 37°C. After washing, the amount of A dot-enzyme immunoassay was used for screening MAbs against 10 P. aeruginosa clinical strains isolated from the sputum of CF patients. Elastase (2 pI, produced as above) from each of the P. aeruginosa strains was applied to nitrocellulose paper and allowed to dry at room temperature. Immune specificity was revealed with biotinylated aintimouse IgG as previously described.
Protein (Fig. 2b) An interesting finding in this study is that all clinical and IATS P. aeruginosa strains presenting elastase as demonstrated by SDS-PAGE and/or elastolytic activity shared the two same separate epitopes as revealed by their interaction with the MAbs ELA-17 and ELA-42 (Table 1 ). The pattern of conservation of the two other epitopes is less common since ELA-207 and ELA-45 reacted, respectively, with only 50 and 40% of the clinical strains tested and the latter reacted with 66% of the IATS strains. We must consider that this difference in epitope specificities of elastase among P. aeruginosa strains may also influence the structure and/or activity of the elastase molecule secreted by the different groups of P. aeruginosa strains.
